Key result
Lipid-lowering therapy use in heFH patients increased from 59% to 78% over follow-up, yet only 13% achieved target LDL-C levels.
Observational (n=2,317)
Open-label
Yes
Answers are grounded in this paper and cite their sources.
Objective. To evaluate compliance of patients with heterozygous familial hypercholesterolemia (heFH) for 5-year period in the RENAISSANCE registry (Registry of patients with familial hypercholesterolemia and very high cardiovascular risk with insufficient effect of lipid-lowering therapy). Material and methods. The RENAISSANCE registry is an open, national, observational study and includes FH patients. We analyzed atherosclerosis risk factors, history of CVD and adherence to LLT. Serum total cholesterol, triglycerides, high-density lipoprotein cholesterol were measured in all centers. LDL-C level was defined according to Friedewald formula. Results. The study included 2317 heterozygous FH patients (58% of female); 59% ones had high cardiovascular risk. Follow-up visits were conducted in 47% of subjects, median follow-up period was 24 months [11; 42]. Such patients had a definite heterozygous FH and hereditary history of CVD. They were younger and diagnosed with FH at an earlier age compared to patients without follow-up who had more common modifiable risk factors (p<0.05). In the group of high cardiovascular risk, 54% of patients received LLT, in the group with very high cardiovascular risk — 86%. The number of patients taking LLT increased from 59% to 78% throughout the follow-up period (statins at the highest dose — from 36% to 54%, combination with ezetimibe — 34% from 15%, PCSK9 inhibitors — 14% from 4% (p<0.001)). The target LDL-C level was reached by 13% of patients. Simulation analysis data showed that at least 92.5% of patients with heterozygous FH in the registry must receive combination of statins, ezetimibe and PCSK9 inhibitors for adequate LDL-C control. Conclusion. A five-year follow-up of participants in the RENAISSANCE registry shows more common combinations of LLT. Nevertheless, it is insufficient for adequate LDL-C control.
No takes yet. Share an insight, caveat, or question.
Чубыкина et al. (2023) conducted an observational in Heterozygous familial hypercholesterolemia (n=2,317). Lipid-lowering therapy (statins, ezetimibe, PCSK9 inhibitors) vs. Baseline lipid-lowering therapy adherence was evaluated on Adherence to lipid-lowering therapy (LLT) and target LDL-C achievement (p=<0.001). Lipid-lowering therapy use in heFH patients increased from 59% to 78% over follow-up, yet only 13% achieved target LDL-C levels.
Synapse has enriched 10 related papers. Consider them for comparative context: